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Summary
Background Cancer is associated with an increased risk of thromboembolic diseases, but data on the association 
between prostate cancer and thromboembolic diseases are scarce. We investigated the risk of thromboembolic disease 
in men with prostate cancer who were receiving endocrine treatment, curative treatment, or surveillance.
Methods We analysed data from PCBaSe Sweden, a database based on the National Prostate Cancer Register, which 
covers over 96% of prostate cancer cases in Sweden. Standardised incidence ratios (SIR) of deep-venous thrombosis 
(DVT), pulmonary embolism, and arterial embolism were calculated by comparing observed and expected (using the 
total Swedish male population) occurrences of thromboembolic disease, taking into account age, calendar-time, 
number of thromboembolic diseases, and time since previous thromboembolic disease. 
Findings Between Jan 1, 1997, and Dec 31, 2007, 30 642 men received primary endocrine therapy, 26 432 curative 
treatment, and 19 526 surveillance. 1881 developed a thromboembolic disease. For men on endocrine therapy, risks for 
DVT (SIR 2·48, 95% CI 2·25–2·73) and pulmonary embolism (1·95, 1·81–2·15) were increased, although this was not 
the case for arterial embolism (1·00, 0·82–1·20). Similar patterns were seen for men who received curative treatment 
(DVT: 1·73, 1·47–2·01; pulmonary embolism: 2·03, 1·79–2·30; arterial embolism: 0·95, 0·69–1·27) and men who 
were on surveillance (DVT: 1·27, 1·08–1·47; pulmonary embolism: 1·57, 1·38–1·78; arterial embolism: 1·08, 0·87–1·33). 
Increased risks for thromboembolic disease were maintained when patients were stratiﬁ ed by age and tumour stage.
Interpretation All men with prostate cancer were at higher risk of thromboembolic diseases, with the highest risk for 
those on endocrine therapy. Our results indicate that prostate cancer itself, prostate cancer treatments, and selection 
mechanisms all contribute to increased risk of thromboembolic disease. Thromboembolic disease should be a 
concern when managing patients with prostate cancer. 
Funding Swedish Research Council, Stockholm Cancer Society, and Cancer Research UK. 
Introduction
Cancer is a risk factor for thromboembolic disease, and 
patients with cancer are estimated to be around four times 
more likely to develop a thrombosis than a similar 
individual without cancer.1 Treatments for cancer might 
also increase the risk of thromboembolic disease. For 
prostate cancer, deep-venous thrombosis (DVT) and 
thromboembolism are common complications after 
prostatectomy, with risks ranging from 0·5% to 40% in the 
30 days after the operation.2–5 Additionally, the risk of 
thromboembolic disease increases exponentially with age.6 
While several studies have investigated whether patients 
with prostate cancer treated with endocrine treatment are 
at higher risk for cardiovascular disease, few population-
based studies have investigated the risk of thromboembolic 
disease following endocrine treatment.7–9 During the 1980s, 
Varenhorst and colleagues8,9 reported a positive association 
between the use of cyproterone acetate (a steroidal anti-
androgen) and ﬁ brinolytic activity, suggesting a decreased 
risk of thromboembolism. A more recent study, including 
11 199 men with prostate cancer, of whom 229 had a venous 
thromboembolism after diagnosis, showed a greater risk 
of venous thrombosis associated with cyproterone acetate 
than with gonadrotropin releasing-hormone (GNRH) 
agonists or orchiectomy.7 
Investigation of the risk of thromboembolic disease 
after endocrine treatment is important for several 
reasons. Testosterone is thought to have a 
cardioprotective eﬀ ect, since androgen receptors have 
been identiﬁ ed on the cardiomyocytes and the valves of 
the heart.10–15 Preliminary experimental ﬁ ndings have 
suggested that androgens might have a role in the 
regulation of arterial thrombosis through their eﬀ ect 
on platelet activation.16 Endocrine treatment is used in a 
large proportion of men with prostate cancer during 
the course of the disease, and is the cornerstone 
treatment for men with locally advanced or metastatic 
prostate cancer.17,18 The indications for endocrine 
treatment have been widening because of more active 
treatment in men with advanced disease, and because 
of neoadjuvant and adjuvant use in men with localised 
high-risk tumours, resulting in more men of all ages 
and with all types of prostate tumour receiving 
endocrine treatment for longer periods.19 
We studied a comprehensive population-based cohort 
with complete follow-up through record linkage of 
pertinent registers, to assess the risk of thrombo-
embolic disease in men with prostate cancer who had 
received curative treatment, surveillance, or endocrine 
treatment. 
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Methods
Data collection 
PCBaSe Sweden is based on the National Prostate Cancer 
Register (NPCR) of Sweden, which started in 1996 and 
captures more than 96% of all newly diagnosed, biopsy-
conﬁ rmed prostate cancers. This compares favourably 
with the Swedish Cancer Registry,20  which misses less than 
3·7% of prostate cancer cases.21 The NPCR includes date of 
diagnosis, age at diagnosis, tumour stage, tumour 
diﬀ erentiation, serum concentration of prostate cancer-
speciﬁ c antigen (PSA) at the time of diagnosis, and primary 
treatment given or planned up to 6 months after the date 
of diagnosis. The validity of primary treatment registered 
in NPCR is more than 90% for curative treatment and 
surveillance, and more than 95% for endocrine treatment 
(Stattin P, unpublished). A more detailed description of 
NPCR is given elsewhere.22
Patients had been treated in accordance with regional 
clinical care guidelines. Because of PSA screening, the 
rate of curative treatment increased dramatically during 
the period of study, whereas the rate of primary endocrine 
treatment was more or less constant over the same period. 
The proportion of men with localised disease put on 
surveillance decreased during this time.22 Most endocrine 
treatment was with GNRH agonists or orchiectomy, 
although anti-androgens (not combined with other 
endocrine treatment) were prescribed in about 10% of 
cases. Maximum androgen blockade was never 
recommended in the guidelines. Most anti-androgens 
used during the registration period were non-steroidal—
ie, ﬂ utamide and bicalutamide. Cyproterone acetate was 
not recommended as a primary endocrine treatment, and 
was only used as second-line treatment in selected cases. 
For hormone-resistant prostate cancers, oestrogens and 
estramustine phosphate were prescribed most often.22
By using the Swedish 10-digit personal identity 
number, PCBaSe was linked to other national registers, 
allowing for information on demographics, 
comorbidities, socio economic status, and causes of 
death to be collected.23,24 In 1987, the Hospital Discharge 
Register started collecting information regarding in-
patient care. Each record contains medical information 
on surgical and anaesthetic procedures, hospital 
department, and discharge diagnoses coded according to 
the WHO International Classiﬁ cation of Diseases 10 
(ICD10).23 For heart diseases, the primary diagnoses have 
been shown to be correct in around 95% of cases, as 
judged by the European Society of Cardiology diagnosis 
guidelines.25–27 Socioeconomic characteristics were 
assessed by record linkages to the 1960–90 5-yearly 
census databases, and based on socioeconomic status. 
Socioeconomic status is based on occupational group, 
and stratiﬁ es men into white-collar worker (salaried 
professionals or educated workers who perform a semi-
professional oﬃ  ce, administrative, or sales coordination), 
blue-collar worker (manual workers), not gainfully 
employed, and unknown.24 As of 1997, the Cause of 
Death Register collected date and underlying cause of 
death coded according to ICD10.23 Detailed information 
on the data content of PCBaSe is given elsewhere.28 
For our analyses, the following information was taken 
from PCBaSe: age, serum concentrations of PSA, and 
treatment information at time of diagnosis, tumour grade 
and stage, socioeconomic status, history of thromboembolic 
disease (primary diagnoses), and date of death. Gleason 
score was used to assess tumour grade. If WHO tumour 
grade was reported primarily instead of Gleason score 
(25% of men), conversion to Gleason score was done as 
follows: G1=Gleason 2–6, G2=Gleason 7, and G3=Gleason 
8–10. Prostate cancer stage was deﬁ ned based on the 
Tumour, Node, Metastasis (TNM) stages used in the NPCR 
(panel).22 Men with prostate cancer were selected if they 
received curative treatment, surveillance, or endocrine 
treatment as primary treatment. The curative treatment 
group consisted of men who underwent radical 
prostatectomy and/or radiotherapy. Endocrine treatment 
was grouped into anti-androgens, oestrogens, orchiectomy, 
GNRH agonists, GNRH agonist combined with long-term 
anti-androgens, and other types of endocrine treatment. 
The Swedish central ethics committee (Dnr Ö 14-2007) 
and the ethics committee at Umeå University 
(Dnr 07-049M) approved this study.
Statistical analysis
We analysed the relation between the diﬀ erent types of 
prostate cancer treatment and subtypes of thromboem-
bolic disease: DVT (ICD10: I80–82), pulmonary embolism 
(ICD10: I26), and arterial embolism (ICD10: K55, I74). 
Since PCBaSe is based on the entire Swedish population, 
standardised incidence ratios (SIR) could be calculated 
by comparing observed events in the selected cohort 
(men with prostate cancer) with the expected events in 
the Swedish male population. The number of events for 
this standard population was based on the number of 
men in Sweden each year on Dec 31 (Register of the Total 
Population 1997–2007).23,24 All numbers of events were 
based on the ﬁ rst event of thromboembolic disease after 
a diagnosis of prostate cancer.
Panel: Prostate cancer stage grouping in the National 
Prostate Cancer Register (NPCR) of Sweden
1 Localised (prostate-speciﬁ c antigen [PSA] <20 ng/mL)—
T0–2, N0 or NX, M0 or MX, all grades, PSA <20 ng/mL 
2 Localised (PSA ≥20 ng/mL but <50 ng/mL): T0–2, N0 or 
NX, M0 or MX, all grades, PSA ≥20 ng/mL but <50 ng/mL 
3  Locally advanced—T3–4, N0 or NX, M0 or MX, all grades, 
PSA <50 ng/mL
4  Intermediate group—M0 or MX, PSA ≤100 ng/mL, not in 
stage group 1, 2, or 3 
5  Metastatic disease—M1 or PSA >100 ng/mL 
6  Missing data—Missing T or N or M category/categories or 
missing grade or missing PSA 
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The SIRs were thus deﬁ ned as the ratio of the observed 
number of a particular thromboembolic disease to the 
expected number of that thromboembolic disease. The 
calculations of these SIRs are explained in detail in 
the webappendix. Brieﬂ y, observed numbers of thrombo-
embolic disease were counted among the men with 
prostate cancer, and were obtained from the Hospital 
Discharge Register (1987–2007). Expected numbers were 
calculated by multiplying time of follow-up with the 
corresponding age-speciﬁ c and period-speciﬁ c incidence 
rates. Time of follow-up was taken from the observed 
numbers of thromboembolic disease, and age-speciﬁ c and 
period-speciﬁ c incidence rates were calculated as the 
incidence of thromboembolic disease in the background 
population divided by the corresponding person-time in 
this background population. All calculations took 
thromboembolic disease history into account, since men 
with a history of previous thromboembolism are at an 
increased risk for being diagnosed with prostate cancer or 
a subsequent thromboembolic disease.29 The 95% CI for 
the SIRs were estimated by assuming that the observed 
cases had a Poisson distribution using Byar’s normal 
approximation.30,31 To take comorbidities into account 
before prostate cancer diagnosis, SIR calculations were 
also stratiﬁ ed by history of ischaemic heart disease (ICD10: 
I20-25), circulatory disease (ICD10: I00-I99), and stroke 
(ICD10: I60–64, G45). All analyses were stratiﬁ ed by 
tumour stage and age group (<65, 65–74, and ≥75 years). 
Endocrine treatment Curative treatment Surveillance
Total endocrine 
treatment group
Anti-androgens Orchiectomy GNRH agonists GNRH agonists plus 
short-term anti-
androgen therapy
Total (n) 30 642* 3391 5340 9066 11 646 26 432 19 526
Mean follow-up time (SD) 3·5 (2·4) 4·0 (2·4) 3·1 (2·3) 3·8 (2·4) 3·3 (2·3) 4·4 (2·5) 4·7 (2·7)
Age group (years)
<65 2941 (9·6) 546 (16·1) 208 (3·9) 731 (8·1) 1140 (9·8) 13 677 (51·7) 2535 (13·0)
65–74 9255 (30·2) 1505 (44·4) 1128 (21·1) 2706 (29·8) 3499 (30·0) 10 956 (41·4) 7526 (38·5)
≥75 18 446 (60·2) 1340 (39·5) 4004 (75·0) 5629 (62·1) 7007 (60·2) 1799 (6·8) 9465 (48·5)
Date period
1997–99 8503 (27·7) 534 (15·7) 2114 (39·6) 3113 (34·3) 2316 (19·9) 3849 (14·6) 5470 (28·0)
2000–02 9669 (31·6) 1099 (32·4) 1507 (28·2) 2848 (31·4) 3850 (33·1) 6732 (25·5) 5618 (28·8)
2003–06 12 470 (40·7) 1758 (51·8) 1719 (32·2) 3105 (34·2) 5480 (47·1) 15 851 (60·0) 8438 (43·2)
Gleason score
2–6 6042 (19·7) 1016 (30·0) 851 (15·9) 2005 (22·1) 1961 (16·8) 15 325 (58·0) 13 277 (68·0)
7 12 192 (39·8) 1438 (42·4) 2069 (38·7) 3588 (39·6) 4690 (40·3) 8153 (30·8) 4687 (24·0)
8–10 11 562 (37·7) 877 (25·9) 2236 (41·9) 3205 (35·4) 4696 (40·3) 2729 (10·3) 1152 (5·9)
Missing data 846 (2·8) 60 (1·8) 184 (3·4) 268 (3·0) 299 (2·6) 225 (0·9) 410 (2·1)
Prostate cancer stage group
Localised: PSA <20 ng/mL 4298 (14·0) 838 (24·7) 469 (8·8) 1516 (16·7) 1348 (11·6) 18 850 (71·3) 12 879 (66·0)
Localised: PSA ≥20 ng/mL but <50 ng/mL 3317 (10·8) 516 (15·2) 460 (8·6) 1101 (12·1) 1158 (9·9) 2247 (8·5) 2411 (12·3)
Locally advanced 5323 (17·4) 643 (19·0) 829 (15·5) 1779 (19·6) 1931 (16·6) 2600 (9·8) 1696 (8·7)
Intermediate 4845 (15·8) 635 (18·7) 706 (13·2) 1561 (17·2) 1740 (14·9) 853 (3·2) 750 (3·8)
Metastatic disease or PSA >100 ng/mL 12 139 (39·6) 671 (19·8) 2726 (51·0) 2845 (31·4) 5269 (45·2) 592 (2·2) 456 (2·3)
Missing data 720 (2·3) 88 (2·6) 150 (2·8) 264 (2·9) 200 (1·7) 1290 (4·9) 1334 (6·8)
Civil status
Married 19 630 (64·1) 2356 (69·5) 3202 (60·0) 5768 (63·6) 7488 (64·3) 19451 (73·6) 13 379 (68·5)
Single 10 980 (35·8) 1033 (30·5) 2128 (39·9) 3291 (36·3) 4147 (35·6) 6972 (26·4) 6118 (31·3)
Missing data 32 (0·1) 2 (0·1) 10 (0·2) 7 (0·1) 11 (0·1) 9 (0·1) 29 (0·1)
Socioeconomic status
White collar 13 049 (42·6) 1749 (51·6) 1929 (36·1) 3839 (42·3) 4959 (42·6) 14 322 (54·2) 9203 (47·1)
Blue collar 17 105 (55·8) 1592 (46·9) 3334 (62·4) 5066 (55·9) 6504 (55·8) 11 805 (44·7) 10 052 (51·5)
Not gainfully employed/missing data 488 (1·6) 50 (1·5) 77 (1·4) 161 (1·8) 183 (1·6) 305 (1·2) 271 (1·4)
Thromboembolic disease at baseline
Yes 1143 (3·7) 92 (2·7) 194 (3·6) 376 (4·1) 440 (3·8) 487 (1·8) 649 (3·3)
No 29 499 (96·3) 3299 (97·3) 5146 (96·4) 8690 (95·9) 11 206 (96·2) 25 945 (98·2) 18 877 (96·7)
*Includes 1119 men who were treated with other types or combinations of endocrine therapy. Data are n (%) unless otherwise stated. GNRH=gonadotropin-releasing hormone. PSA=prostate cancer-speciﬁ c 
antigen. SD=standard deviation.
Table 1: Baseline characteristics of men with prostate cancer according to their treatment in PCBaSe Sweden
See Online for webappendix
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Poisson regression was used to adjust the SIRs for cancer 
stage, history of thromboembolic disease, and 
socioeconomic status. The absolute risk diﬀ erences by 
diﬀ erent types of thromboembolic disease and prostate 
cancer treatment were calculated, and sensitivity analyses 
were done to test the assumption of intention-to-treat. 
Finally, we calculated the bias in the SIRs due to using the 
general population rates to estimate the expected numbers 
of thromboembolic disease, based on the formulas by 
Jones and Swerdlow.32 Statistical analyses were done with 
SAS version 9.1.3, and R version 2.7.2. 
Role of the funding source
The funding organisations had no inﬂ uence on the 
design and conduct of the study, data collection, 
management, analysis, interpretation, and preparation, 
review, or approval of the manuscript. The corresponding 
author had full access to all data, and the ﬁ nal 
responsibility to submit the manuscript for publication.
Results
Between Jan 1, 1997, and Dec 31, 2007, PCBaSe registered 
76 600 men diagnosed with prostate cancer, of whom 
30 642 received endocrine treatment as their primary 
treatment. Speciﬁ cally, 3391 men received anti-androgen 
therapy; 5340 underwent orchiectomy; 9066 received a 
GNRH agonist; and 11 646 men received GNRH agonists 
combined with short-term anti-androgen therapy (table 1). 
The remaining 1199 men were treated with other types or 
combinations of endocrine treatment. The remaining 
45 958 men received either curative treatment (n=26 432) 
or surveillance (n=19 526; table 1). 
The characteristics of the study population are shown 
in table 1. 18 446 (60·2%) of the men given endocrine 
treatment were aged 75 years or more, compared with 
9465 (48·5%) of those on surveillance, and 1799 (6·8%) of 
those who received curative treatment. Men treated with 
anti-androgens were younger on average than men treated 
with other types of endocrine treatment (table 1). In the 
endocrine treatment group, 4298 (14·0%) patients had a 
localised tumour and PSA concentration less than 20 ng/
mL, compared with 12 879 (66·0%) in the surveillance 
group, and 18 850 (71·3%) in the curative treatment group. 
In the group treated with anti-androgens, 838 (24·7%) 
men had localised tumours, compared with 643 (19·0%) 
with locally advanced disease, and 671 (19·8%) with 
metastatic disease. 2845 (31·4%) men treated with GNRH 
agonists had metastatic disease, while 2726 (51·0%) men 
treated with orchiectomy had metastatic disease. 
1881 men developed a thromboembolic disease after 
being diagnosed with prostate cancer: 767 men had a DVT, 
873 a pulmonary embolism, and 241 an arterial embolism. 
In the total group with prostate cancer, the SIR was 1·90 
(95% CI 1·77–2·04) for DVT, 1·85 (1·73–1·97) for 
pulmonary embolism, and 1·02 (0·89–1·15) for arterial 
embolism. When analysed according to prostate cancer 
treatment, the risks for DVT and pulmonary embolism 
were increased irrespective of whether patients received 
endocrine treatment, were treated curatively, or were on 
surveillance (table 2). No increased risk for arterial 
embolism was noted in any of the groups. Results 
according to prostate cancer treatment were also analysed 
for diﬀ erent strata of comorbidities before prostate cancer 
diagnosis, but there was no indication of eﬀ ect modiﬁ cation 
by history of any circulatory disease (data not shown).
Detailed analysis showed that adjustment for Gleason 
score or civil status did not alter the SIRs appreciably 
(data not shown), but diﬀ erent eﬀ ects by age and tumour 
stage at time of diagnosis were found. Age-stratiﬁ ed and 
tumour-stratiﬁ ed analyses showed a larger SIR for men 
younger than 75 years, and for those with metastatic 
disease, in each treatment group (table 3). Overall, the 
SIRs for DVT were larger for men on endocrine treatment 
than for men who had undergone curative treatment or 
men who were on surveillance, but there was not such a 
distinct pattern for pulmonary embolism (table 3). 
In age-stratiﬁ ed analyses for diﬀ erent types of endocrine 
treatment, the smallest SIR for both DVT and pulmonary 
embolism was noted for men treated with anti-androgens, 
whereas the largest was seen for orchiectomy (table 4). 
The numbers of men with arterial embolism were too 
small to do this subanalysis. The age eﬀ ect seen for the 
overall endocrine treatment group in table 3 was also 
noted for each type of endocrine treatment, although it 
was less strong because endocrine treatment preferences 
vary by age—around 20% of the men in the two younger 
age groups received anti-androgens, and 9% underwent 
orchiectomy, whereas in men aged 75 years and over a 
higher proportion underwent orchiectomy (20%) and a 
lower proportion received anti-androgens (10%). 
Sensitivity analyses excluding men who had an event of 
thromboembolic disease within 31 days after prostate 
Patients with prostate cancer on 
endocrine treatment
Patients with prostate cancer on 
curative treatment 
Patients with prostate cancer on 
surveillance 
 SIR (95% CI) Obs/Exp SIR (95% CI) Obs/Exp SIR (95% CI) Obs/Exp
Deep-venous thrombosis 2·48 (2·25–2·73) 436/175·6 1·73 (1·47–2·01) 160/92·7 1·27 (1·08–1·47) 171/135·1
Pulmonary embolism 1·95 (1·81–2·15) 380/195·2 2·03 (1·79–2·30) 248/122·1 1·57 (1·38–1·78) 245/155·6
Arterial embolism 1·00 (0·82–1·20) 108/108·5 0·95 (0·69–1·27) 44/46·4 1·08 (0·87–1·33) 89/82·1
Obs=observed. Exp=expected.
Table 2: Standard incidence ratios (SIR) with 95% CI for diﬀ erent groups of patients with prostate cancer patients in PCBaSe Sweden
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cancer diagnosis did not alter the previous ﬁ ndings 
signiﬁ cantly: changes in SIRs ranged between 0% and 
0·50% (data not shown). Additionally, we analysed the 
time between prostate cancer diagnosis and ﬁ rst event of 
thromboembolic disease (table 5). Increased risks for 
thromboembolic events for all treatment groups seem to 
be dominated by events occurring during the ﬁ rst 
18 months after diagnosis, but an increased risk was still 
noted after more than 4 years. A more detailed analysis of 
curative treatment indicated that the risks were highest 
during the ﬁ rst 6 months, and were higher for radical 
prostatectomy than for radiotherapy (data not shown). 
Table 6 shows the absolute risk of DVT and pulmonary 
embolism for diﬀ erent prostate cancer treatment 
groups. The largest absolute risks were seen for DVT 
and for men on endocrine treatment. For the general 
population, it can be seen that the absolute risk for DVT 
was higher among men aged 75 years and over than for 
those aged under 75 years (table 7); by contrast, the 
absolute risk for DVT in men treated with endocrine 
Endocrine treatment Curative treatment Surveillance
SIR (95% CI) Obs/Exp SIR (95% CI) Obs/Exp SIR (95% CI) Obs/Exp
Deep-venous thrombosis
All tumour stages*
<65 years 6·18 (4·56–8·20) 48/7·8 2·22 (1·74–2·78) 74/33·4 1·07 (0·46–2·11) 8/7·5
65–74 years 3·09 (2·61–3·63) 148/47·9 1·42 (1·11–1·80) 70/49·1 1·27 (0·97–1·64) 61/47·9
≥75 years 2·00 (1·75–2·27) 240/120 1·57 (0·89–2·54) 16/10·2 1·28 (1·04–1·55) 102/79·8
Localised tumours
<65 years 2·77 (0·56–8·09) 3/1·1 2·03 (1·53–2·63) 56/27·6 0·91 (0·33–1·98) 6/6·6
65–74 years 1·53 (0·94–2·33) 21/13·8 1·34 (0·99–1·77) 50/37·3 1·23 (0·91–1·64) 47/38·1
≥75 years 1·66 (1·26–2·13) 60/36·2 1·03 (0·38–2·25) 6/5·8 1·17 (0·90–1·49) 66/56·4
Intermediate tumours
<65 years 4·78 (2·67–7·88) 15/3·1 2·48 (1·19–4·56) 10/4 2·38 (0·03–13·26) 1/0·4
65–74 years 3·03 (2·28–3·96) 54/17·8 1·84 (1·05–2·99) 16/8·7 1·77 (0·88–3·16) 11/6·2
≥75 years 1·96 (1·57–2·43) 85/43·3 2·56 (0·83–5·98) 5/2 1·49 (0·92–2·28) 21/14·1
Metastatic tumours
<65 years 8·63 (5·82–12·32) 30/3·5 14·37 (5·25–31·29) 6/0·4 16·37 (0·21–91·10) 1/0·1
65–74 years 4·22 (3·25–5·37) 65/15·4 3·89 (0·78–11·36) 3/0·8 1·85 (0·21–6·66) 2/1·1
≥75 years 2·34 (1·87–2·89) 86/36·8 2·41 (0·27–8·71) 2/0·8 1·28 (0·26–3·73) 3/2·3
Pulmonary embolism
All tumour stages*
<65 years 4·92 (3·60–6·56) 46/9·4 1·93 (1·55–2·37) 90/46·7 2·22 (1·39–3·37) 22/9·9
65–74 years 1·89 (1·54–2·29) 104/55·1 2·01 (1·68–2·39) 128/63·6 1·44 (1·14–1·78) 82/57
≥75 years 1·76 (1·54 – 2·00) 230/130·7 2·53 (1·71–3·62) 30/11·8 1·59 (1·34–1·87) 141/88·7
Localised tumours
<65 years 1·40 (0·16–5·04) 2/1·4 1·72 (1·33–2·18) 67/39 2·03 (1·20–3·21) 18/8·9
65–74 years 1·31 (0·82–1·99) 22/16·8 1·93 (1·56–2·36) 95/49·2 1·34 (1·03–1·72) 62/46·2
≥75 years 1·39 (1·05–1·79) 58/41·8 2·76 (1·66–4·30) 19/6·9 1·56 (1·27–1·90) 100/64·1
Intermediate tumours
<65 years 4·74 (2·81–7·50) 18/3·8 3·18 (1·85–5·10) 17/5·3 6·38 (1·28–18·63) 3/0·5
65–74 years 1·55 (1·06–2·19) 32/20·7 2·26 (1·45–3·36) 24/10·6 2·05 (1·12–3·44) 14/6·8
≥75 years 1·76 (1·4–2·19) 83/47·1 1·86 (0·50–4·77) 4/2·1 1·13 (0·66–1·81) 17/15
Metastatic tumours
<65 years 6·42 (4·2–9·41) 26/4 1·88 (0·02–10·47) 1/0·5 0 (NA–53·27) 0/0·1
65–74 years 2·95 (2·18–3·90) 49/16·6 3·47 (0·70–10·15) 3/0·9 4·82 (1·55–11·24) 5/1
≥75 years 2·08 (1·64–2·59) 79/38·1 3·29 (0·66–9·62) 3/0·9 1·73 (0·46–4·42) 4/2·3
Arterial embolism
All tumour stages*
<65†, 65–74†, ≥75† 1·29 (0·35–3·31) 4/3·1 0·94 (0·50–1·60) 13/13·9 0·64 (0·07–2·30) 2/3·1
NA=not available. Obs=observed. Exp=expected. *Includes patients with missing data on stage (see panel for deﬁ nitions of tumour stages). †Not broken down by age group 
due to small numbers. 
Table 3: Standard incidence ratios (SIR) for diﬀ erent groups of thromboembolic diseases in patients with prostate cancer according to their treatment 
and stratiﬁ ed by age and tumour stage
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treatment was comparable for younger and older men. 
Therefore, the absolute risk increase after exposure to 
endocrine treatment was larger for those in the youngest 
age groups (<65 years and 65–74 years) than those in 
the oldest age group. The pattern was similar for 
pulmonary embolism (data not shown).
Finally, we calculated the possible bias in the SIRs due 
to using general population rates to estimate expected 
numbers of thromboembolic disease. The true relative 
risk (RR) of DVT was deﬁ ned as SIR×(1–Prev)/
(1–(Prev×SIR)), where the prevalence (Prev) of men with 
prostate cancer receiving endocrine treatment was 
estimated to be 560/100 000.33 This resulted in the 
following bias: [(RR–SIR)/SIR]×100=[(2·50–2·48)/2·48]×
100=0·84%, indicating that including men with prostate 
cancer in the general population only resulted in a 
deviation of less than 1% from the so-called true SIR 
estimates. The size of the bias was similar for other 
thromboembolic diseases and other treatment groups 
(data not shown).
Discussion
In this large population-based study, we compared the 
risk of thromboembolic disease between Swedish men 
with prostate cancer and Swedish men in the background 
population. The ﬁ ndings show that men with prostate 
cancer are at a higher risk for thromboembolic disease 
than are men without prostate cancer. The risk was 
increased for DVT and pulmonary embolism, but not for 
arterial embolism, and was especially high for men 
treated with endocrine treatment. Additionally, the relative 
risk of thromboembolic disease in men treated with 
endocrine therapy was higher for younger men (<65 years) 
and for men with metastatic disease, while the absolute 
risk was similar for all three age groups (<65, 65–74, and 
≥75 years). Moreover, a smaller increase in risk was found 
for men treated with anti-androgens compared with the 
other types of endocrine treatment. 
The underlying mechanisms for the higher risk of 
thromboembolic disease could have several explanations. 
First, a baseline risk might be present because of 
physiological alterations due to the tumour, which seems 
to be supported by the fact that the risk of thromboembolic 
disease increases as tumour stage increases. Second, the 
diﬀ erent patterns of risk associated with diﬀ erent types 
of treatment indicate that treatments, and the selection 
of these treatments, can aﬀ ect the risk of thromboembolic 
disease. Curative treatment, such as prostatectomy, and 
surveillance are also associated with an increased risk of 
thromboembolic disease, and indicate that some men 
might have received surveillance because of ongoing 
comorbidities.34 Third, the higher risks, through each 
Anti-androgens Orchiectomy GNRH agonists GNRH agonists plus short-term 
anti-androgen therapy
 SIR (95% CI) Obs/Exp SIR (95% CI) Obs/Exp SIR (95% CI) Obs/Exp SIR (95% CI) Obs/Exp
Deep-venous thrombosis
All ages 1·56 (1·03–2·27) 27/17·3 2·81 (2·26–3·45) 90/32·1 2·42 (2·04–2·86) 142/58·6 2·51 (2·13–2·94) 154/61·3
<65 years* 1·14 (0·21–6·36) ·· 1·76 (0·23–13·51) ·· 4·03 (0·94–17·32) ·· 2·32 (0·53–10·16) ··
65–74 years† 0·69 (0·27–1·73) ·· 1·36 (0·54–3·42) ·· 0·96 (0·41–2·23) ·· 1·38 (0·60–3·17) ··
≥75 years† 0·98 (0·47–2·07) ·· 1·81 (1·03 –3·18) ·· 1·49 (0·89–2·50) ·· 1·30 (0·76–2·22) ··
Pulmonary embolism
All ages 1·35 (0·91–1·94) 29/21·4 2·26 (1·77–2·84) 73/32·4 1·84 (1·52–2·20) 118/64·1 2·00 (1·68–2·36) 141/70·6
<65 years* 0·23 (0·03–1·73) ·· 0·65 (0·08–5·50) ·· 0·63 (0·10–4·08) ·· 0·36 (0·05–2·42) ··
65–74 years† 0·46 (0·16–1·36) ·· 0·77 (0·25–2·36) ·· 0·83 (0·31–2·20) ·· 0·82 (0·31–2·21) ··
≥75 years† 0·81 (0·39–1·67) ·· 1·17 (0·62–2·18) ·· 0·84 (0·47–1·51) ·· 0·98 (0·54 –1·77) ··
Obs=observed. Exp=expected. *Adjusted for tumour stage, socioeconomic status, and history of thromboembolic disease. †Adjusted for tumour stage, history of 
thromboembolic disease, socioeconomic status, and 5-year age groups. GNRH=gonadotropin-releasing hormone.
Table 4: Standard incidence ratios (SIR) for diﬀ erent groups of thromboembolic disease by type of endocrine treatment
Endocrine treatment Curative treatment Surveillance
SIR (95% CI) Obs/Exp SIR (95% CI) Obs/Exp SIR (95% CI) Obs/Exp
Deep-venous thrombosis (all tumour stages*)
0–6 months 3·13 (2·52–3·84) 91/29·1 4·10 (3·01–5·45) 47/11·5 1·68 (1·11–2·43) 28/16·7
7–18 months 2·12 (1·73–2·58) 99/46·6 1·81 (1·28–2·50) 37/20·4 1·54 (1·12–2·06) 45/29·2
1·5–4 years 2·33 (1·97–2·73) 152/65·3 1·17 (0·84–1·58) 41/35·2 1·09 (0·82–1·42) 55/50·4
>4 years 2·71 (2·19–3·32) 94/34·6 1·36 (0·95–1·90) 35/25·7 1·11 (0·80–1·49) 43/38·7
Pulmonary embolism (all tumour stages*)
0–6 months 2·57 (2·00–3·25) 69/26·9 6·57 (5·23–8·16) 82/12·5 1·45 (0·92–2·18) 23/15·8
7–18 months 2·00 (1·62–2·44) 95/47·6 2·21 (1·66–2·88) 54/24·4 1·64 (1·21–2·17) 49/29·9
1·5–4 years 1·68 (1·40–2·01) 124/73·7 1·21 (0·92–1·57) 56/46·2 1·44 (1·15–1·79) 82/56·9
>4 years 1·96 (1·58–2·4) 92/47 1·44 (1·09–1·87) 56/39 1·72 (1·38–2·11) 91/53
Arterial embolism (all tumour stages*)
0–6 months 0·68 (0·34–1·22) 11/16·1 1·78 (0·81–3·39) 9/5 0·58 (0·19–1·35) 5/8·6
7–18 months 1·07 (0·71–1·55) 28/26·2 1·10 (0·53–2·02) 10/9·1 0·70 (0·35–1·25) 11/15·7
1·5–4 years 1·00 (0·72–1·35) 41/41·1 0·75 (0·40–1·29) 13/17·2 NA 0/0
>4 years 1·11 (0·74–1·61) 28/25·1 0·80 (0·41–1·40) 12/15 1·57 (1·13–2·11) 43/27·4
*Includes patients with missing data on stage (see panel for deﬁ nitions of tumour stages). Obs=observed. 
Exp=expected.
Table 5: Standard incidence ratios (SIR) for diﬀ erent groups of patients with prostate cancer in PCBaSe 
Sweden stratiﬁ ed by time since prostate cancer diagnosis
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stage of the analysis, for men primarily treated with 
endocrine treatment indicate a risk conferred by 
endocrine treatment over and above the other treatments 
and indications for treatment.
People with cancer have an increased risk of 
thromboembolic disease. Even though this association 
has long been recognised in clinical practice, few studies 
have quantiﬁ ed this risk for men with prostate cancer in 
detail.7,35,36 High rates of thrombosis have been reported 
in other cancers, especially in people with advanced 
disease receiving antitumour treatment. Clinical trials on 
breast cancer reported a rate of thrombosis of 1–10% in 
women with node-positive breast cancer, whereas 
development of venous thrombosis was reported in 10% 
of women with advanced ovarian cancer and in up to 
28% of people with malignant gliomas.36
Treatment for prostate cancer can also be associated 
with an increased risk of thromboembolic disease. 
A cohort study based on 5951 patients undergoing 
prostatectomy showed an incidence of 0·5% (95% CI 
0·4–0·7) for symptomatic DVT and pulmonary 
embolism.35 Additionally, a British study including 
11 199 men with advanced prostate cancer showed that 
patients treated with cyproterone acetate had a signiﬁ cantly 
higher risk for venous thromboembolism than did men 
who underwent orchiectomy or were prescribed GNRH 
agonists (adjusted odds ratio 5·23, 95% CI 3·12–8·79).7 
We caution that the observed contrasts in thromboembolic 
disease between diﬀ erent treatment groups should be 
interpreted as how treatment and treatment selection 
modify the risk of thromboembolic disease in men with 
prostate cancer. For several reasons, this study cannot 
directly quantify how much the observed diﬀ erences in 
thromboembolic disease risk between treatment groups 
are due to the treatments themselves.1 Factors taken into 
account during the process of selecting treatment might 
also be associated with risk of thromboembolic disease. 
During the period of time covered by our study, Swedish 
men with early-stage prostate cancer who received curative 
treatment had lower all-cause mortality than the 
background population. Most men receiving curative 
treatment were recommended surgery, and had to be 
healthy enough to undergo radical prostatectomy.34 We 
made a similar observation in our study: men 75 years or 
older who had undergone curative treatment had a much 
lower absolute risk for DVT than men of the same age in 
the standard population, illustrating a selection bias 
towards healthy men for radiotherapy and prostatectomy. 
The increased risk of thromboembolism in the group 
treated with curative intent occurred mainly during the 
ﬁ rst 6 months of follow-up, indicating that the surgical 
intervention was important. However, a selection 
phenomenon might lead to a wrong conclusion about the 
eﬀ ect of surgery in a direct comparison with the ﬁ rst period 
of follow-up in, for example, men under surveillance.2 
There might have been diﬀ erences in diagnostic activity 
(frequency of check-ups and diﬀ erences in the types of 
testing used) for thromboembolic disease between the 
groups. However, DVT is likely to be correctly diagnosed 
and clinically relevant in patients admitted to hospital, who 
were the only ones included in this study. Therefore, we 
avoided the possibility that surveillance would lead to the 
diagnoses of many asymptomatic DVTs not related to the 
cancer or the treatment. Vigilance for thromboembolic 
disease is likely to have been similar in men with advanced 
cancer and those oﬀ ered curative treatment, but might 
have been less intense in men under surveillance. It is also 
possible that a rapidly fatal pulmonary embolism in 
patients with advanced cancer could be interpreted as the 
fatal end-stage of the cancer, and therefore not coded in 
hospital charts. However, this misclassiﬁ cation would only 
aﬀ ect a smaller number of patients, and mainly those on 
endocrine treatment, biasing their estimates towards null.3 
The comparison between the treatment groups might be 
confounded by the introduction of second-line treatment—
eg, men treated with curative intent or surveillance will 
have been exposed to endocrine treatment when the 
disease progressed. 
Experimental ﬁ ndings have suggested a link between 
prostate cancer and thromboembolic disease, which 
might lead to hypotheses for further mechanistic studies. 
Babiker and colleagues37 showed that the early release of 
Absolute risk for men 
with prostate cancer
Absolute risk for men in 
the general population
Absolute risk diﬀ erence 
(95% CI)
Endocrine treatment
<65 years 4·43 0·72 3·71 (2·46 to 4·96)
65–74 years 4·05 0·39 3·66 (3·00 to 4·31)
≥75 years 4·04 2·58 1·45 (0·94 to 1·96)
Curative treatment
<65 years 1·23 0·55 0·67 (0·39 to 0·95)
65–74 years 1·44 0·61 0·83 (0·49 to 1·17)
≥75 years 2·84 5·29 –2·45 (–3·84 to –1·06)
Surveillance
<65 years 0·66 0·62 0·04 (–0·41 to 0·50)
65–74 years 0·66 0·41 0·25 (–0·01 to 0·51)
≥75 years 3·40 2·77 0·64 (0·07 to 1·21)
Table 7: Absolute risk and absolute risk diﬀ erence of deep-venous thrombosis by prostate cancer 
treatment and age group in PCBaSe Sweden
Absolute risk for men 
with prostate cancer
Absolute risk for men in 
the general population
Absolute risk 
diﬀ erence (95% CI)
Deep-venous thrombosis
Endocrine treatment 4·08 1·64 2·44 (2·05–2·82)
Curative treatment 1·40 0·81 0·59 (0·37–0·80)
Surveillance 1·89 1·49 0·39 (0·11–0·68)
Pulmonary embolism
Endocrine treatment 3·55 1·83 1·73 (1·37–2·09)
Curative treatment 2·17 1·07 1·10 (0·83–1·37)
Surveillance 2·70 1·72 0·99 (0·65–1·33)
Table 6: Absolute risk and absolute risk diﬀ erence for deep-venous thromboembolism and pulmonary 
embolism disease by prostate cancer treatment in PCBaSe Sweden 
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prostasomes from prostate cancer cells into the 
circulation might evoke blood-clotting eﬀ ects causing 
thromboembolic disease. Another study by Li and 
colleagues16 showed a possible link between endocrine 
treatment and thromboembolic disease, in which they 
noted that the prevention of experimental arterial 
thrombosis by the use of androgens at physiological 
concentrations is mediated by the androgen receptor 
through modulation of platelet activation. Some studies 
have also suggested that testosterone has an 
antithrombotic eﬀ ect, because higher concentrations are 
associated with an increase in antithrombin 3.9,38,39 This 
possible antithrombotic eﬀ ect of testosterone is supported 
by our treatment-speciﬁ c analyses of endocrine treatment, 
which showed that men treated with anti-androgens have 
the lowest SIR. Anti-androgens block the androgen 
receptors in the prostate, but do not decrease the 
circulating concentrations of total testosterone. Because 
of the eﬀ ect of anti-androgens in the hypothalamus, the 
testosterone concentrations in serum might even be 
increased, and thus androgen-dependent pathways in 
other organs can still function.40 
The higher SIRs in the youngest age group (table 3) 
can be explained by a lower absolute thromboembolic 
disease risk for younger men than for older men in the 
general population, and similar absolute risks for younger 
and older men with prostate cancer. This age eﬀ ect was 
seen within each tumour stage; however, a stronger eﬀ ect 
was seen for those with metastatic disease at time of 
diagnosis, suggesting that advanced cancer potentiates 
the risk due to the associated predisposition for 
thromboembolic disease. From a public-health point of 
view, both the absolute risk and absolute risk diﬀ erence 
were largest for men given endocrine treatment. Thus, 
the largest number of extra cases of thromboembolic 
disease are likely to be seen in this patient group. 
The NPCR database contains data from more than 
76 000 men with prostate cancer, and provides complete 
follow-up for each patient, as well as linkage to other 
registers that allow for detailed information on 
thromboembolic disease morbidity. The same information 
about thromboembolic disease was available for the entire 
general population, which enabled us to adjust all 
comparisons for history of thromboembolic disease. 
Milder, non-hospitalised cases of thromboembolic 
disease, such as asymptomatic DVT, were not included, 
thus there is a possible underestimation of SIRs. The bias 
in the SIRs due to the use of general population rates, 
which included men with prostate cancer, to estimate 
expected numbers of thromboembolic disease was found 
to be negligible. The eﬀ ect of treatment choice on the 
results should be small, since both history of 
thromboembolic disease and stage of disease were 
adjusted for. However, the above notwithstanding, there 
might be some residual bias that cannot be accounted for. 
For example, choice of endocrine treatment is likely to be 
related to comorbidity, suggesting that there could be a 
selection bias. However, as suggested by Miettinen,41 the 
physician or patient’s choice of endocrine treatment 
primarily constitutes a confounder for the study of the 
intended eﬀ ect (palliative treatment for prostate cancer), 
but not for the study of side-eﬀ ects such as thromboembolic 
disease. This is because at the time the data were collected, 
the literature did not suggest a strong association between 
endocrine treatment and cardio vascular side-eﬀ ects, thus 
it was not standard clinical practice to take thromboembolic 
disease history into account when initiating treatment. 
The diagnosis of prostate cancer itself can also bias the 
results, because these men receive more intensive medical 
care (eg, increased number of clinical visits), and are 
therefore more likely to be diagnosed with a thrombo-
embolic disease event when it occurs. Furthermore, the 
combination of prostate cancer, especially advanced 
disease, with thromboembolic disease might strengthen 
the indication for hospitalisation, therefore biasing the 
SIR estimates upwards. Based on the Swedish Drug 
Registry, it was shown that it takes about 1 month before 
men with prostate cancer start taking their endocrine 
treatment (Stattin P, unpublished). The eﬀ ect of delayed 
start of treatment was assessed with a sensitivity analysis 
excluding cardiovascular disease events that occurred 
within 1 month of the prostate cancer diagnosis, and 
showed almost no change in SIR estimates (data not 
shown). Furthermore, an unknown proportion of men 
treated curatively, on surveillance, or on anti-androgens, 
subsequently changed to GNRH agonists, which could 
dilute a true diﬀ erence in risk between anti-androgens 
and GNRH agonists. We had no information about 
smoking habits, diabetes, body-mass index, or 
hypertension, but none of these factors are strongly 
associated with prostate-cancer risk, and are therefore 
unlikely to explain the current ﬁ ndings.42 No information 
was available on history of comorbidities other than 
circulatory diseases.
Our ﬁ ndings indicate that it is important to consider 
thromboembolic side-eﬀ ects when treating patients with 
prostate cancer, especially those who require endocrine 
treatment. Higher risks for thromboembolic disease 
were also noted for younger men and men with metastatic 
disease. Risk patterns for thromboembolic disease that 
diﬀ er according to prostate-cancer treatment, age, and 
tumour stage, are probably explained by the physiological 
eﬀ ects of prostate cancer, treatments for prostate cancer, 
and the factors taken into consideration when selecting 
these treatments. 
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